Your browser is no longer supported. Please, upgrade your browser.
Settings
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Index- P/E- EPS (ttm)-2.75 Insider Own1.30% Shs Outstand38.95M Perf Week4.44%
Market Cap2.22B Forward P/E- EPS next Y-3.38 Insider Trans-19.08% Shs Float32.44M Perf Month-23.72%
Income-103.10M PEG- EPS next Q-0.82 Inst Own78.70% Short Float8.91% Perf Quarter-4.75%
Sales8.40M P/S263.84 EPS this Y22.10% Inst Trans-0.04% Short Ratio3.86 Perf Half Y51.90%
Book/sh3.49 P/B16.30 EPS next Y-5.60% ROA-38.30% Target Price88.67 Perf Year56.97%
Cash/sh4.73 P/C12.04 EPS next 5Y- ROE-61.70% 52W Range21.98 - 82.49 Perf YTD97.43%
Dividend- P/FCF- EPS past 5Y1.20% ROI-41.10% 52W High-31.02% Beta0.93
Dividend %- Quick Ratio8.10 Sales past 5Y30.80% Gross Margin- 52W Low158.87% ATR3.10
Employees212 Current Ratio8.10 Sales Q/Q-19.40% Oper. Margin- RSI (14)36.52 Volatility4.83% 5.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-46.00% Profit Margin- Rel Volume0.59 Prev Close56.02
ShortableYes LT Debt/Eq0.27 EarningsAug 07 BMO Payout- Avg Volume749.73K Price56.90
Recom1.70 SMA20-6.21% SMA50-17.27% SMA20012.92% Volume439,739 Change1.57%
Jul-30-19Downgrade Guggenheim Buy → Neutral
Jul-08-19Reiterated Cantor Fitzgerald Overweight $81 → $94
Apr-12-19Initiated Piper Jaffray Overweight $80
Mar-29-19Initiated Robert W. Baird Outperform $85
Mar-04-19Reiterated Chardan Capital Markets Buy $70 → $100
Feb-25-19Reiterated Cantor Fitzgerald Overweight $68 → $81
Feb-11-19Reiterated H.C. Wainwright Buy $60 → $73
Dec-31-18Resumed B. Riley FBR Buy $72
Nov-26-18Reiterated H.C. Wainwright Buy $48 → $60
Jul-27-18Initiated Cantor Fitzgerald Overweight $58
Jun-28-18Initiated B. Riley FBR, Inc. Buy $50
May-16-18Initiated Wells Fargo Outperform $47
May-07-18Reiterated Leerink Partners Outperform $26 → $63
Jan-04-18Initiated Janney Buy $25
Dec-01-17Initiated H.C. Wainwright Buy $28
Nov-07-17Initiated Evercore ISI Outperform $22
Oct-20-17Reiterated Leerink Partners Outperform $17 → $19
Dec-06-16Reiterated WallachBeth Buy $27 → $15
Nov-22-16Downgrade Jefferies Buy → Hold
Nov-16-16Downgrade Piper Jaffray Overweight → Neutral
Aug-16-19 06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Jul-31-19 06:28AM  Introducing uniQure (NASDAQ:QURE), The Stock That Soared 653% In The Last Three Years Simply Wall St.
Jul-29-19 08:35AM  UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.38%
07:18AM  uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Jul-26-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Jul-19-19 12:15PM  Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of Shares GuruFocus.com
Jul-11-19 05:33AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised) Zacks
Jul-09-19 11:07AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study Zacks
Jul-08-19 08:19AM  What Drove uniQure 171% Higher in the First Half of 2019 Motley Fool
Jul-06-19 07:00AM  uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B GlobeNewswire
Jul-02-19 06:02AM  How Much Of uniQure N.V. (NASDAQ:QURE) Do Institutions Own? Simply Wall St.
Jun-29-19 08:25AM  The Week Ahead In Biotech: Pending Clinical Readouts In Focus Benzinga
Jun-22-19 09:33PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Jun-21-19 07:00AM  uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) GlobeNewswire
Jun-20-19 09:41AM  The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
Jun-18-19 09:15AM  Fed Week Begins in the Green Zacks
Jun-17-19 04:21PM  Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst Investor's Business Daily +11.84%
09:41AM  Gene-Therapy Firm UniQure Explores Options Including Sale Bloomberg
09:33AM  UniQure Jumps on Report It's Exploring a Possible Sale TheStreet.com
Jun-11-19 08:47AM  Is the Options Market Predicting a Spike in uniQure (QURE) Stock? Zacks -12.02%
Jun-05-19 11:53AM  AMD and 3 more momentum stocks to watch MarketWatch
07:08AM  An Intrinsic Calculation For uniQure N.V. (NASDAQ:QURE) Suggests It's 29% Undervalued Simply Wall St.
Jun-04-19 09:01AM  uniQure (QURE) Jumps: Stock Rises 8.9% Zacks +9.44%
May-31-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
May-30-19 02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
May-22-19 07:00AM  uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntingtons Disease GlobeNewswire
May-10-19 04:16PM  This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study Investor's Business Daily +6.67%
02:44PM  uniQure N.V. (NASDAQ:QURE) Insiders Have Been Selling Simply Wall St.
08:00AM  uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
May-07-19 07:00AM  uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting GlobeNewswire
May-02-19 04:26PM  Did Hedge Funds Drop The Ball On Uniqure NV (QURE) ? Insider Monkey
07:00AM  uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting GlobeNewswire
May-01-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Apr-29-19 07:07AM  UniQure: 1Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Apr-15-19 12:15PM  uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire
08:43AM  Want an insiders way to play IPOs? This fund has had outsize success with its strategy MarketWatch
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
07:00AM  uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntingtons Disease GlobeNewswire
Apr-04-19 02:36PM  uniQure N.V. (NASDAQ:QURE): Financial Strength Analysis Simply Wall St. +5.86%
Mar-29-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-01-19 09:29PM  Why Big Pharma Is Diving Into Gene Therapy Barrons.com +6.15%
07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Feb-28-19 07:00AM  uniQure Announces 2018 Financial Results and Highlights Recent Company Progress GlobeNewswire
Feb-27-19 09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
07:00AM  uniQure Presents New Preclinical Data on AMT-130 at the CHDIs 14th Annual Huntingtons Disease Therapeutics Conference GlobeNewswire
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
09:15AM  Deal on the Way Now that Deadline is Delayed? Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
07:19AM  2 More Gene Therapy Stocks on Big Pharma's Buyout Radar Motley Fool
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga +34.30%
Feb-22-19 07:45AM  Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences Discovering Underlying Factors of Influence GlobeNewswire
Feb-15-19 07:24AM  uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids GlobeNewswire
Feb-13-19 10:29AM  How Does Investing In uniQure N.V. (NASDAQ:QURE) Impact The Volatility Of Your Portfolio? Simply Wall St. -5.88%
Feb-08-19 07:26AM  UniQure gene therapy shows rise in blood-clotting protein in trial Reuters +9.98%
07:00AM  uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Feb-04-19 07:00AM  uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B GlobeNewswire
Jan-30-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Jan-22-19 07:00AM  uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntingtons Disease GlobeNewswire
Dec-18-18 02:13AM  Uniqure NV (QURE): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-12-18 10:14AM  Do Institutions Own uniQure N.V. (NASDAQ:QURE) Shares? Simply Wall St.
Dec-04-18 09:12AM  FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Zacks
Dec-03-18 07:00AM  uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B GlobeNewswire
Nov-30-18 08:00AM  Analysis: Positioning to Benefit within Vivint Solar, uniQure N.V, Internap, Intuit, WideOpenWest, and Deere Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-29-18 01:39PM  Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma Investor's Business Daily
Nov-23-18 06:57AM  Novartis Gets Approval for Gene Therapy Luxturna in Europe Zacks
Nov-19-18 12:15PM  uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day GlobeNewswire -9.11%
Nov-16-18 12:45PM  Uniqure CEO discusses company's positive data in hemophil... CNBC Videos
08:35AM  uniQure Up on Positive Data From Mid-Stage Hemophilia Study Zacks
Nov-15-18 11:59AM  Why uniQure N.V. Stock Is Skyrocketing Today Motley Fool +35.66%
07:00AM  uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Nov-13-18 08:45AM  Options Traders Expect Huge Moves in uniQure (QURE) Stock Zacks
Nov-06-18 08:35AM  UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:27AM  UniQure: 3Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress GlobeNewswire
Nov-05-18 07:00AM  uniQure to Host Research & Development Day on Monday, November 19 in New York City GlobeNewswire
Oct-31-18 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Oct-23-18 07:45AM  Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-18-18 06:55AM  uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies GlobeNewswire
Oct-17-18 07:00AM  uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting GlobeNewswire
Oct-16-18 07:00AM  uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) GlobeNewswire
Sep-28-18 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Sep-24-18 07:00AM  uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Sep-13-18 08:50AM  Implied Volatility Surging for uniQure (QURE) Stock Options Zacks
Sep-10-18 06:00AM  Achillion Appoints Paul Firuta Chief Operating Officer GlobeNewswire
Aug-30-18 07:00AM  uniQure to Participate at Multiple Upcoming Conferences GlobeNewswire
Aug-27-18 12:14PM  Play The Future of Gene Therapy With These 5 Biotech Stocks InvestorPlace
Aug-23-18 07:00AM  uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Aug-21-18 08:30AM  Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-08-18 08:40AM  UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:34AM  UniQure: 2Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress GlobeNewswire
Jul-13-18 03:35PM  3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure Investor's Business Daily
Jun-28-18 03:18PM  3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy Benzinga +13.58%
07:00AM  uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Jun-25-18 08:49AM  Are These 3 Red-Hot Gene Therapy Stocks Still Buys? Motley Fool
Jun-13-18 07:00AM  uniQure Announces New Appointments to its Board of Directors GlobeNewswire
Jun-06-18 08:30AM  Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Astley-Sparke PhilipDirectorAug 01Sale60.126,460388,3446,812Aug 05 12:21 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJul 17Sale71.458,000571,616399,230Jul 19 10:37 AM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 19Sale77.458,000619,626407,230Jun 20 11:03 AM
Astley-Sparke PhilipDirectorJun 03Sale63.636,000381,77913,272Jun 04 02:07 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMay 15Sale58.388,000467,017415,230May 17 03:48 PM
KLEMT CHRISTIANChief Accounting OfficerApr 16Sale57.181,54688,40054,539Apr 17 11:09 AM
Astley-Sparke PhilipDirectorApr 01Sale59.846,000359,04019,272Apr 03 12:22 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 14Sale63.0919,6881,242,081423,230Mar 15 03:15 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 13Sale64.3247,6883,067,216442,918Mar 15 03:15 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsFeb 15Option Exercise5.3120,000106,20046,578Feb 20 02:18 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsFeb 15Sale35.828,000286,56038,578Feb 20 02:18 PM
Kaye JackDirectorJan 28Sale31.311,21037,88514,934Jan 31 05:19 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale31.4219,085599,651490,028Jan 30 07:15 PM
Balachandran MadhavanDirectorJan 28Sale31.311,21037,8856,812Jan 30 05:32 PM
Soteropoulos PaulaDirectorJan 28Sale31.321,21037,89719,934Jan 30 05:28 PM
SCHAFFER DAVIDDirectorJan 28Sale31.311,21037,88545,721Jan 30 05:24 PM
Astley-Sparke PhilipDirectorJan 28Sale31.321,21037,89725,272Jan 30 05:20 PM
van Deventer SanderChief Scientific OfficerJan 28Sale31.311,35842,51940,313Jan 30 05:01 PM
KLEMT CHRISTIANChief Accounting OfficerJan 28Sale31.291,47946,27856,085Jan 30 04:57 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsJan 28Sale31.291,05232,91726,578Jan 30 04:55 PM
McMillan Scott T.Chief Operating OfficerJan 28Sale31.2359118,45720,432Jan 30 04:52 PM
Springhorn Jeremy P.DirectorJan 28Sale31.321,21037,8976,812Jan 30 04:49 PM
SCHAFFER DAVIDDirectorJan 17Sale30.717,500230,32543,701Jan 29 08:32 PM
KLEMT CHRISTIANChief Accounting OfficerJan 03Sale27.915,739160,17540,000Jan 07 11:21 AM
Astley-Sparke PhilipDirectorDec 03Sale30.395,000151,95023,252Dec 06 09:38 AM